05-Nov-2018 - Plasticell Ltd

Plasticell receives EU funding as part of €3.7 million consortium

Parkinson´s, Huntington´s and Demyelination diseases to be tackeled

Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, has announced that the Advanced Stem Cell Training Network (ASCTN), a European research consortium in which the company is a partner organisation, has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson´s, Huntington´s and Demyelination disease - which are caused by acute or progressive loss of cells in the brain.

“Neurodegeneration is a hallmark of many incurable diseases that are fast becoming major global health problems as the world’s elderly population continues to increase”, commented Dr Yen Choo, founder and Executive Chairman of Plasticell. “Discovering effective treatments for these conditions will require a deeper understanding of disease mechanisms, as well as more effective drug screening strategies, both of which will benefit from better cellular models of neurodegeneration.”

Alongside Plasticell, the research Network also comprises: the Karolinska Institute, San Raffaele Hospital, Cardiff University, University of Barcelona, Autonomous University of Madrid, Institute for Bioengineering of Catalonia, Technical University of Dresden and Poietis SA. ASCTN is funded by the European Union Horizon 2020 Programme (H2020-MSCA-ITN-2018) under the Marie Skłodowska-Curie Initial Training Network and Grant Agreement No. 813851.

The different participating laboratories specialise in human stem cell manipulation, combinatorial cell culture, directed neuronal and glial differentiation, microfluidics and single cell analysis, advanced imaging, brain-on-chip and 3D tissue engineering. Moreover, other key specialisms include cerebral organoids, ex vivo gene expression, direct cellular reprograming, mouse genetic modification, animal models of neurological disease, scaffold implantation and stem cell transplants into the brain.

Plasticell’s CombiCult® combinatorial cell culture technology will specifically be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models. Of particular interest is a brain-on-chip model to study interactions between patient iPSC-derived striatal medium spiny neurons (MSN) and dopaminergic neurons.

“We are delighted to be part of this exciting European consortium of scientists and engineers who will apply diverse technologies to produce patient-specific human neural models in test tubes, microchips or model organisms,” Dr Choo added.

Facts, background information, dossiers
  • Plasticell
  • neurodegeneration
  • funding
  • organoids
  • neurological disorders
More about Plasticell
  • News

    Plasticell and GSK sign collaboration agreement

    Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells ( ... more

    Plasticell appoints Dr Aaron T. T. Chuang as Chief Scientific Officer

    Plasticell has recruited Dr Aaron Chuang to its executive management team in the role of Chief Scientific Officer (CSO).  Prior to this appointment, Dr Chuang served as Research Director at the Regenerative Medicine unit of GlaxoSmithKline (GSK), where he worked for over 18 years. As Plasti ... more

    Plasticell wins £1.6 million funding

    Plasticell has announced that Innovate UK has made a further investment in a therapeutic programme utilising CombiCult®, the high throughput stem cell technology designed to solve bottlenecks in regenerative medicine development. Innovate UK will provide a grant of approximately £1.3 millio ... more

  • Companies

    Plasticell Ltd

    Plasticell is a mature biotech company focusing on the development of small molecule drugs that act on progenitor cells, for use in regenerative medicine. Plasticell is able to identify molecules that encourage progenitor cells to differentiate, potentially allowing for the development of ... more